Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia.
Timothée KlopfensteinVincent GendrinAurélie GerazimeThierry ConrozierJean-Charles BalblancPierre-Yves RoyerAnne LohseChaouki MezherLynda TokoCerise GuillochonJulio BadieAlix PierronN 'dri Juliette Kadiane-OussouMarc PuyraveauSouheil Zayetnull nullPublished in: Infectious diseases and therapy (2021)
Tocilizumab is an effective treatment in hospitalized patients with COVID-19 and hypoxemia by improving survival and decreasing mechanical ventilation requirement. The greatest benefit is observed in severe COVID-19.
Keyphrases
- systematic review
- mechanical ventilation
- coronavirus disease
- meta analyses
- sars cov
- rheumatoid arthritis
- acute respiratory distress syndrome
- respiratory failure
- intensive care unit
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- respiratory syndrome coronavirus
- randomized controlled trial
- early onset
- clinical trial
- disease activity
- systemic lupus erythematosus
- replacement therapy
- drug induced